Survival of encapsulated human primary fibroblasts and erythropoietin expression under xenogeneic conditions

Human Gene Therapy

Volumn 15, Issue 7, 2004, Pages 669-680

  Schwenter, F ^a   Schneider, B L ^a,b   Pralong, W F ^a,b   Deglon N ^a,b   Aebischer, P ^a,b  

^a University of Lausanne Medical Center   (Switzerland)

^b EPFL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; ERYTHROPOIETIN; POLYETHERSULFONE; RETROVIRUS VECTOR; TACROLIMUS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ENCAPSULATION; CELL LINEAGE; CONTROLLED STUDY; FIBROBLAST; GENE DELIVERY SYSTEM; GENE THERAPY; GENETIC ENGINEERING; HEMATOCRIT; HOLLOW FIBER; HUMAN; HUMAN CELL; IMMUNOCOMPETENCE; IMMUNOSUPPRESSIVE TREATMENT; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PIGMENT EPITHELIUM; XENOGRAFT;

ANIMALS; CELL SURVIVAL; CELL TRANSPLANTATION; ERYTHROPOIETIN; FIBROBLASTS; HEMATOCRIT; HUMANS; MICE; MICE, INBRED DBA; POLYMERS; SULFONES; TRANSPLANTATION, HETEROLOGOUS;

ANIMALIA; MUS MUSCULUS; UNIDENTIFIED RETROVIRUS;

EID: 3142663065     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/1043034041361172     Document Type: Article

References (57)

1. AEBISCHER, P., SCHLUEP, M., DEGLON, N., JOSEPH, J.M., HIRT, L., HEYD, B., GODDARD, M., HAMMANG, J.P., ZURN, A.D., KATO, A.C., REGLI, F., and BAETGE, E.E. (1996). Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients. Nat. Med. 2, 696-699.
2. BARR, E., and LEIDEN, J.M. (1991). Systemic delivery of recombinant proteins by genetically modified myoblasts. Science 254, 1507-1509.
3. BARTHOLOMEW, A., PATIL, S., MACKAY, A., NELSON, M., BUYANER, D., HARDY, W., MOSCA, J., STURGEON, C., SIATSKAS, M., MAHMUD, N., FERRER, K., DEANS, R., MOSELEY, A., HOFFMAN, R., and DEVINE, S.M. (2001). Baboon mesenchymal stem cells can be genetically modified to secrete human erythropoietin in vivo. Hum. Gene Ther. 12, 1527-1541.
4. BENHAMOU, P.Y., MULLEN, Y., SHAKED, A., BAHMILLER, D., and CSETE, M.E. (1996). Decreased alloreactivity to human islets secreting recombinant viral interleukin 10. Transplantation 62, 1306-1312.
5. BESSIS, N., COTTARD, V., SAIDENBERG-KERMANACH, N., LEMEITER, D., FOURNIER, C., and BOISSIER, M.C. (2002). Syngeneic fibroblasts transfected with a plasmid encoding interleukin-4 as non-viral vectors for anti-inflammatory gene therapy in collagen-induced arthritis. J. Gene Med. 4, 300-307.
6. BOHL, D., NAFFAKH, N., and HEARD, J.M. (1997). Long-term control of erythropoietin secretion by doxycycline in mice transplanted with engineered primary myoblasts. Nat. Med. 3, 299-305.
7. BRAUKER, J., MARTINSON, L.A., YOUNG, S.K., and JOHNSON, R.C. (1996). Local inflammatory response around diffusion chambers containing xenografts: Nonspecific destruction of tissues and decreased local vascularization. Transplantation 61, 1671-1677.
8. BRAUKER, J., FROST, G.H., DWARKI, V., NIJJAR, T., CHIN, R., CARR-BRENDEL, V., JASUNAS, C., HODGETT, D., STONE, W., COHEN, L.K., and JOHNSON, R.C. (1998). Sustained expression of high levels of human factor IX from human cells implanted within an immunoisolation device into athymic rodents. Hum. Gene Ther. 9, 879-888.
9. BRAUNER, R., NONOYAMA, M., LAKS, H., DRINKWATER, D.C., JR., MCCAFFERY, S., DRAKE, T., BERK, A.J., SEN, L., and WU, L. (1997). Intracoronary adenovirus-mediated transfer of immunosuppressive cytokine genes prolongs allograft survival. J. Thorac. Cardiovasc. Surg. 114, 923-933.
10. BROOKS, S.V. (1998). Rapid recovery following contraction-induced injury to in situ skeletal muscles in max mice. J. Muscle Res. Cell Motil. 19, 179-187.
11. BUCHSER, E., GODDARD, M., HEYD, B., JOSEPH, J.M., FAVRE, J., DE TRIBOLET, N., LYSAGHT, M., and AEBISCHER, P. (1996). Immunoisolated xenogenic chromaffin cell therapy for chronic pain: Initial clinical experience. Anesthesiology 85, 1005-1012; discussion 29A-30A.
12. CHANG, P.L., SHEN, N., and WESTCOTT, A.J. (1993). Delivery of recombinant gene products with microencapsulated cells in vivo. Hum. Gene Ther. 4, 433-440.
13. CHEN, B.F., CHANG, W.C., CHEN, S.T., CHEN, D.S., and HWANG, L.H. (1995). Long-term expression of the biologically active growth hormone in genetically modified fibroblasts after implantation into a hypophysectomized rat. Hum. Gene Ther. 6, 917-926.
14. CHRISTENSEN, R., GUTTLER, F., and JENSEN, T. (2002). Comparison of epidermal keratinocytes and dermal fibroblasts as potential target cells for somatic gene therapy of phenylketonuria. Mol. Genet. Metab. 76, 313.
15. COLE, D.R., WATERFALL, M., MCINTYRE, M., and BAIRD, J.D. (1992). Microencapsulated islet grafts in the BB/E rat: A possible role for cytokines in graft failure. Diabetologia 35, 231-237.
16. DAI, Y.F., ROMAN, M., NAVIAUX, R.K., and VERMA, I.M. (1992a). Gene therapy via primary myoblasts: Long-term expression of factor IX protein following transplantation in vivo. Proc. Natl. Acad. Sci. U.S.A. 89, 10892-10895.
17. DAI, Y.F., QIU, X.F., XUE, J.L., and LIU, Z.D. (1992b). High efficient transfer and expression of human clotting factor IX cDNA in cultured human primary skin fibroblasts from hemophilia B patient by retroviral vectors. Sci. China Ser. B Chem. Life Sci. Earth Sci. 35, 183-193.
18. DALLE, B., PAYEN, E., REGULIER, E., DEGLON, N., ROUYERFESSARD, P., BEUZARD, Y., and AEBISCHER, P. (1999). Improvement of mouse β-thalassemia upon erythropoietin delivery by encapsulated myoblasts. Gene Ther. 6, 157-161.
19. DESCAMPS, V., BLUMENFELD, N., PERRICAUDET, M., BEUZARD, Y., and KREMER, E.J. (1995). Organoids direct systemic expression of erythropoietin in mice. Gene Ther. 2, 411-417.
20. DUNN, K.C., AOTAKI-KEEN, A.E., PUTKEY, F.R., and HJELMELAND, L.M. (1996). ARPE-19, a human retinal pigment epithelial cell line with differentiated properties. Exp. Eye Res. 62, 155-169.
21. EMERICH, D.F., WINN, S.R., HARPER, J., HAMMANG, J.P., BAETGE, E.E., and KORDOWER, J.H. (1994). Implants of polymer-encapsulated human NGF-secreting cells in the nonhuman primate: Rescue and sprouting of degenerating cholinergic basal forebrain neurons. J. Comp. Neurol. 349, 148-164.
22. ESCHBACH, J.W., KELLY, M.R., HALEY, N.R., ABELS, R.I., and ADAMSON, J.W. (1989). Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N. Engl. J. Med. 321, 158-163.
23. FALQUI, L., MARTINENGHI, S., SEVERINI, G.M., CORBELLA, P., TAGLIETTI, M.V., ARCELLONI, C., SARUGERI, E., MONTI, L.D., PARONI, R., DOZIO, N., POZZA, G., and BORDIGNON, C. (1999). Reversal of diabetes in mice by implantation of human fibroblasts genetically engineered to release mature human insulin. Hum. Gene Ther. 10, 1753-1762.
24. FAVRE, D., BLOUIN, V., PROVOST, N., SPISEK, R., PORROT, F., BOHL, D., MARME, F., CHEREL, Y., SALVETTI, A., HURTREL, B., HEARD, J.M., RIVIERE, Y., and MOULLIER, P. (2002). Lack of an immune response against the tetracycline- dependent transactivator correlates with long-term doxycycline-regulated transgene expression in nonhuman primates after intramuscular injection of recombinant adeno-associated virus. J. Virol. 76, 11605-11611.
25. HAMAMORI, Y., SAMAL, B., TIAN, J., and KEDES, L. (1994). Persistent erythropoiesis by myoblast transfer of erythropoietin cDNA. Hum. Gene Ther. 5, 1349-1356.
26. HAMAMORI, Y., SAMAL, B., TIAN, J., and KEDES, L. (1995). Myoblast transfer of human erythropoietin gene in a mouse model of renal failure. J. Clin. Invest. 95, 1808-1813.
27. JUDGE, T.A., DESAI, N.M., YANG, Z., ROSTAMI, S., ALONSO, L., ZHANG, H., CHEN, Y., MARKMAN, J.F., DEMATEO, R.P., BARKER, C.F., NAJI, A., and TURKA, L.A. (1998). Utility of adenoviral-mediated Fas ligand gene transfer to modulate islet allograft survival. Transplantation 66, 426-434.
28. KANG, S., YI, S., GRIFFITHS, C.E., FANCHER, L., HAMILTON, T.A., and CHOI, J.H. (1998). Calcipotriene-induced improvement in psoriasis is associated with reduced interleukin-8 and increased interleukin-10 levels within lesions. Br. J. Dermatol. 138, 77-83.
29. KIRK, A.D., HARLAN, D.M., ARMSTRONG, N.N., DAVIS, T.A., DONG, Y., GRAY, G.S., HONG, X., THOMAS, D., FECHNER, J.H. Jr., and KNECHTLE, S.J. (1997). CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc. Natl. Acad. Sci. U.S.A. 94, 8789-8794.
30. KOEPKE, J.A. (1991). Microhematocrit method. In: Practical Laboratory Hematology (Churchill Livingstone, New York) pp. 112-114.
31. KOURY, M.J., and BONDURANT, M.C. (1992). The molecular mechanism of erythropoietin action. Eur. J. Biochem. 210, 649-663.
32. KUSAKA, S., FUJIKADO, T., IKEDA, T., and TANO, Y. (1997). Spontaneous disappearance of traumatic macular holes in young patients. Am. J. Ophthalmol. 123, 837-839.
33. LANZA, R.P., BEYER, A.M., and CHICK, W.L. (1994). Xenogenic humoral responses to islets transplanted in biohybrid diffusion chambers. Transplantation 57, 1371-1375.
34. LARSEN, C.P., ELWOOD, E.T., ALEXANDER, D.Z., RITCHIE, S.C., HENDRIX, R., TUCKER-BURDEN, C., CHO, H.R., ARUFFO, A., HOLLENBAUGH, D., LINSLEY, P.S., WINN, K.J., and PEARSON, T.C. (1996). Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 381, 434-438.
35. LIM, F., and SUN, A.M. (1980). Microencapsulated islets as bioartificial endocrine pancreas. Science 210, 908-910.
36. LIU, H.W., OFOSU, F.A., and CHANG, P.L. (1993). Expression of human factor IX by microencapsulated recombinant fibroblasts. Hum. Gene Ther. 4, 291-301.
37. LOUDOVARIS, T., CHARLTON, B., HODGSON, R.J., and MANDEL, T.E. (1992). Destruction of xenografts but not allografts within cell impermeable membranes. Transplant. Proc. 24, 2291-2292.
38. MADSEN, J.C., SUPERINA, R.A., WOOD, K.J., and MORRIS, P.J. (1988). Immunological unresponsiveness induced by recipient cells transfected with donor MHC genes. Nature 332, 161-164.
39. MOULLIER, P., BOHL, D., HEARD, J.M., and DANOS, O. (1993). Correction of lysosomal storage in the liver and spleen of MPS VII mice by implantation of genetically modified skin fibroblasts. Nat. Genet. 4, 154-159.
40. NAFFAKH, N., HENRI, A., VILLEVAL, J.L., ROUYER-FESSARD, P., MOULLIER, P., BLUMENFELD, N., DANOS, O., VAINCHENKER, W., HEARD, J.M., and BEUZARD, Y. (1995). Sustained delivery of erythropoietin in mice by genetically modified skin fibroblasts. Proc. Natl. Acad. Sci. U.S.A. 92, 3194-3198.
41. NAFFAKH, N., PINSET, C., MONTARRAS, D., LI, Z., PAULIN, D., DANOS, O., and HEARD, J.M. (1996). Long-term secretion of therapeutic proteins from genetically modified skeletal muscles. Hum. Gene Ther. 7, 11-21.
42. OSBORNE, W.R., RAMESH, N., LAU, S., CLOWES, M.M., DALE, D.C., and CLOWES, A.W. (1995). Gene therapy for long-term expression of erythropoietin in rats. Proc. Natl. Acad. Sci. U.S.A. 92, 8055-8058.
43. PAGE, S.M., and BROWNLEE, G.G. (1997). An ex vivo keratinocyte model for gene therapy of hemophilia B. J. Invest. Dermatol. 109, 139-145.
44. PALMER, T.D., ROSMAN, G.J., OSBORNE, W.R., and MILLER, A.D. (1991). Genetically modified skin fibroblasts persist long after transplantation but gradually inactivate introduced genes. Proc. Natl. Acad. Sci. U.S.A. 88, 1330-1334.
45. PEDUTO, G., RINSCH, C., SCHNEIDER, B.L., ROLLAND, E., and AEBISCHER, P. (2000). Long-term host unresponsiveness to encapsulated xenogeneic myoblasts after transient immunosuppression. Transplantation 70, 78-85.
46. REGULIER, E., SCHNEIDER, B.L., DEGLON, N., BEUZARD, Y., and AEBISCHER, P. (1998). Continuous delivery of human and mouse erythropoietin in mice by genetically engineered polymer encapsulated myoblasts. Gene Ther. 5, 1014-1022.
47. ROSENTHAL, J.A. (1998). Diaphragmatic paralysis complicating alcohol splanchnic nerve block. Anesth. Analg. 86, 845-846.
48. SCHNEIDER, B.L., PEDUTO, G., and AEBISCHER, P. (2001). A self-immunomodulating myoblast cell line for erythropoietin delivery. Gene Ther. 8, 58-66.
49. SCHNEIDER, B.L., SCHWENTER, F., PRALONG, W.F., and AEBISCHER, P. (2003). Prevention of the initial host immuno-inflammatory response determines the long-term survival of encapsulated myoblasts genetically engineered for erythropoietin delivery. Mol. Ther. 7, 506-514.
50. SCHREZENMEIR, J., KIRCHGESSNER, J., GERO, L., KUNZ, L.A., BEYER, J., and MUELLER-KLIESER, W. (1994). Effect of microencapsulation on oxygen distribution in islets organs. Transplantation 57, 1308-1314.
51. SCHWENTER, F., DEGLON, N., and AEBISCHER, P. (2003). Optimization of human erythropoietin secretion from MLV-infected human primary fibroblasts used for encapsulated cell therapy. J. Gene Med. 5, 246-257.
52. SELDEN, R.F., SKOSKIEWICZ, M.J., HOWIE, K.B., RUSSELL, P.S., and GOODMAN, H.M. (1987). Implantation of genetically engineered fibroblasts into mice: implications for gene therapy. Science 236, 714-718.
53. SERGUERA, C., BOHL, D., ROLLAND, E., PREVOST, P., and HEARD, J.M. (1999). Control of erythropoietin secretion by doxycycline or mifepristone in mice bearing polymer-encapsulated engineered cells. Hum. Gene Ther. 10, 375-383.
54. SVENSSON, E.C., BLACK, H.B., DUGGER, D.L., TRIPATHY, S.K., GOLDWASSER, E., HAO, Z., CHU, L., and LEIDEN, J.M. (1997). Long-term erythropoietin expression in rodents and non-human primates following intramuscular injection of a replication-defective adenoviral vector. Hum. Gene Ther. 8, 1797-1806.
55. M2-gangliosidosis B1 variant. Hum. Gene Ther. 12, 1771-1783.
56. VILLEVAL, J.L., ROUYER-FESSARD, P., BLUMENFELD, N., HENRI, A., VAINCHENKER, W., and BEUZARD, Y. (1994). Retrovirus-mediated transfer of the erythropoietin gene in hematopoietic cells improves the erythrocyte phenotype in murine β-thalassemia. Blood 84, 928-933.
57. ZHOU, S., MURPHY, J.E., ESCOBEDO, J.A., and DWARKI, V.J. (1998). Adeno-associated virus-mediated delivery of erythropoietin leads to sustained elevation of hematocrit in nonhuman primates. Gene Ther. 5, 665-670.